ONS Bridge — Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape

September 17, 2020

Access the presentation on the ONS Bridge:


(Note: you must be registered for the Bridge to view the presentation)

The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate.  As front-line caregivers, oncology nurses are optimally positioned to guide patients through therapy and properly manage adverse events that may arise with this therapy. Additionally, optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes. Oncology nurses must develop best practices for educating patients and monitoring adherence for those receiving oral BTKi therapy.

Supported by an independent educational grant from AstraZeneca.

Target Audience

This activity is designed to meet the educational needs of oncology nurses attending the 2020 ONS Bridge Virtual Meeting.

Learning Objectives

  • Describe the role of the B-cell receptor (BCR) pathway in the survival and proliferation of cancer cells and the rationale for targeting this pathway in CLL/SLL.
  • Examine the latest efficacy data on the use of BTK inhibitors in treatment-naïve and relapsed/refractory CLL and review the most recent guideline recommendations for CLL/SLL management. 
  • Discuss the unique adverse events that may arise with the use of BTK inhibitors and explore evidence-based strategies to ensure the timely recognition and proper management of these adverse events.

Additional Information

Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
09/17/2020 - 9:00am EDT
Event ends: 
09/17/2020 - 10:00am EDT

5 min

Welcome and Introductions/Pre-test

10 min

Targeting the BCR Pathway in CLL: A Novel Approach

20 min

Contemporary Approaches to CLL: Taking a Deep Dive into BTK Inhibition

20 min

Applying Clinical Trial Data to Clinical Practice: Case-based CLL Treatment Strategies for the Oncology Nurse

5 min

Conversations with the Expert/Audience Q&A/Post-test

Live Virtual Event
9:00am EDT
United States

John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology 
Weill Cornell Medicine
New York, New York

Dr. Allan is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York, New York. He received a Bachelor of Science in both Biochemistry and Finance at the University of Missouri in Columbia, Missouri, and completed his medical degree at Saint Louis University School of Medicine in St. Louis, Missouri. Seeking an internal medicine residency program with a particular strength in oncology, Dr. Allan moved to New York to train at New York–Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship.

Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology upon completion of his training, and he is a member of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine.  He treats all lymphoid malignancies and has particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Amy L Goodrich, RN, MSN, CRNP-AC
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins 
Baltimore, Maryland

Amy Goodrich, RN, MSN, CRNP, Research Associate, is a Nurse Practitioner in the Hematologic Malignancies Program and Research Nursing Manager at The Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. Ms. Goodrich manages patients with various types of hematologic malignancies, concentrating on the lymphomas. She also manages the Cancer Center’s research nurses and is extremely involved in research operations.

Ms. Goodrich earned her Master’s Degree in 2000 as an Acute Care Nurse Practitioner from the Johns Hopkins University and her undergraduate nursing degree from the University of Pittsburgh.


Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania


Ms. Rogers is a Nurse Practitioner at Fox Chase Cancer Center in Philadelphia, Pennsylvania. She obtained her BSN from Trenton State College, her MN from UCLA and her post-master’s NP certificate from Temple University. Ms. Rogers has over 40 years of oncology experience with most of that time focused on the care of patients with hematologic malignancies. She has authored many peer-reviewed journal articles and book chapters, as well as given many presentations related to the care of patients with hematologic malignancies and symptom management. Ms. Rogers has held leadership positions in multiple organizations such as serving on the ONS Board of Directors, Chair of the ONS Nominating Committee, and Chair of the Advanced Practice Test Development Committee of the Oncology Nursing Certification Corporation. Currently, she is a member of the Education Committee of the Advanced Practitioner Society for Hematology and Oncology (APSHO).


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
John Allan, MD—has disclosed that he is a consultant for Abbvie, AstraZeneca, BeiGene, Genentech, Janssen, and PCYC. He receives grant/research support from Celgene, Genentech, Janssen, and TG Therapeutics. He is on the speakers' bureau for Abbvie, BeiGene, and PCYC/Janssen.   

Amy L Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant for Gilead, Mylan, and Sandoz.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for Cardinal Health, Genentech, and Merck. She is on the speakers' bureau for AbbVie, Genentech, and Seattle Genetics.

Amy L. Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant for Gilead, Mylan, and Sandoz.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for Cardinal Health, Genentech, and Merck. She is on the speakers' bureau for Abbvie, AstraZeneca, Coherus, and Genentech.

Bryan C. Taylor, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, AOCNS®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Coordination of Care, Diagnosis and Staging, Disease-Related Biology, Oncology Nursing Practice, Professional Practice, Roles of the APN, Scientific Basis for Practice, Symptom Management, and Treatment categories.

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Available Credit

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.